205 related articles for article (PubMed ID: 19840376)
1. CHD5 is down-regulated through promoter hypermethylation in gastric cancer.
Wang X; Lau KK; So LK; Lam YW
J Biomed Sci; 2009 Oct; 16(1):95. PubMed ID: 19840376
[TBL] [Abstract][Full Text] [Related]
2. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
3. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
Fatemi M; Paul TA; Brodeur GM; Shokrani B; Brim H; Ashktorab H
Cancer; 2014 Jan; 120(2):172-80. PubMed ID: 24243398
[TBL] [Abstract][Full Text] [Related]
5. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
[TBL] [Abstract][Full Text] [Related]
6. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
[TBL] [Abstract][Full Text] [Related]
7. Silencing of CHD5 gene by promoter methylation in leukemia.
Zhao R; Meng F; Wang N; Ma W; Yan Q
PLoS One; 2014; 9(1):e85172. PubMed ID: 24454811
[TBL] [Abstract][Full Text] [Related]
8. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
Zhao R; Wang N; Huang H; Ma W; Yan Q
Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
[TBL] [Abstract][Full Text] [Related]
9. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
[TBL] [Abstract][Full Text] [Related]
10. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
11. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.
Zhao R; Yan Q; Lv J; Huang H; Zheng W; Zhang B; Ma W
Lung Cancer; 2012 Jun; 76(3):324-31. PubMed ID: 22186629
[TBL] [Abstract][Full Text] [Related]
12. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma.
Heidari Z; Asemi-Rad A; Moudi B; Mahmoudzadeh-Sagheb H
J Int Med Res; 2022 Jul; 50(7):3000605221105344. PubMed ID: 35808817
[TBL] [Abstract][Full Text] [Related]
13. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
Meng CF; Zhu XJ; Peng G; Dai DQ
World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
[TBL] [Abstract][Full Text] [Related]
14. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer.
Mulero-Navarro S; Esteller M
Epigenetics; 2008; 3(4):210-5. PubMed ID: 18698156
[TBL] [Abstract][Full Text] [Related]
15. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer.
Leung WK; Yu J; Bai AH; Chan MW; Chan KK; To KF; Chan FK; Ng EK; Chung SC; Sung JJ
Mol Carcinog; 2003 Jun; 37(2):91-7. PubMed ID: 12766908
[TBL] [Abstract][Full Text] [Related]
17. Influence of colorectal cancer tumor suppressor gene CHD5 methylation on its clinical and pathological characteristics.
Liu JB; Zhou QB; Xu JZ; Wang GX; Yuan WT
J Biol Regul Homeost Agents; 2015; 29(4):889-93. PubMed ID: 26753653
[TBL] [Abstract][Full Text] [Related]
18. Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas.
He D; Zhang YW; Zhang NN; Zhou L; Chen JN; Jiang Y; Shao CK
Med Oncol; 2015 Apr; 32(4):92. PubMed ID: 25720522
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylations of p16INK4a and p14ARF genes in early and advanced gastric cancer. Correlations of the modes of their occurrence with histologic type.
Tsujimoto H; Hagiwara A; Sugihara H; Hattori T; Yamagishi H
Pathol Res Pract; 2002; 198(12):785-94. PubMed ID: 12608655
[TBL] [Abstract][Full Text] [Related]
20. Role of CHD5 in human cancers: 10 years later.
Kolla V; Zhuang T; Higashi M; Naraparaju K; Brodeur GM
Cancer Res; 2014 Feb; 74(3):652-8. PubMed ID: 24419087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
